Related references
Note: Only part of the references are listed.Apalutamide and Overall Survival in Prostate Cancer
Matthew R. Smith et al.
EUROPEAN UROLOGY (2021)
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Cora N. Sternberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer
Marlon Perera et al.
NATURE REVIEWS UROLOGY (2020)
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
Andrew J. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Ian D. Davis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
Kim N. Chi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score
Kurt Miller et al.
EUROPEAN UROLOGY (2018)
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
N. D. James et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
High PSA anxiety and low health literacy skills: drivers of early use of salvage ADT among men with biochemically recurrent prostate cancer after radiotherapy?
B. A. Mahal et al.
ANNALS OF ONCOLOGY (2015)
Adverse effects of androgen-deprivation therapy in prostate cancer and their management
Handoo Rhee et al.
BJU INTERNATIONAL (2015)
Integrative Clinical Genomics of Advanced Prostate Cancer (vol 161, pg 1215, 2015)
Dan Robinson et al.
CELL (2015)
The Molecular Taxonomy of Primary Prostate Cancer
Adam Abeshouse et al.
CELL (2015)
Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy
Juanita M. Crook et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study
Nigel A. Spry et al.
BJU INTERNATIONAL (2009)
Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions
Anthony V. D'Amico et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Nancy L. Keating et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy
SJ Freedland et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer
MJ Zelefsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression
C Higano et al.
UROLOGY (2004)
The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer
MM Cherrier et al.
JOURNAL OF UROLOGY (2003)
Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial
HJ Green et al.
BJU INTERNATIONAL (2002)
Share Paper
